Search

Your search keyword '"Blasone L"' showing total 7 results
Start Over Author "Blasone L"
7 results on '"Blasone L"'

2. Long term follow-up of liver transplantation (OLT) for cholestatic and autoimmune end stage liver diseases

Author

Blasone, L, Fagiuoli, S, Colledan, M, Strazzabosco, M, Lenzi, M, Floreani, A, Burra, P, Cillo, U, Merenda, R, Donato, M, Rossi, G, Salizzoni, M, Franchello, A, Rizzetto, M, Pinzello, G, De Carlis, L, Toniutto, P, Andorno, E, Blasone L, Fagiuoli S, Colledan M, Strazzabosco M, Lenzi M, Floreani A, Burra P, Cillo U, Merenda R, Donato MF, Rossi G, Salizzoni M, Franchello A, Rizzetto M, Pinzello G, De Carlis L, Toniutto P, Andorno E, Blasone, L, Fagiuoli, S, Colledan, M, Strazzabosco, M, Lenzi, M, Floreani, A, Burra, P, Cillo, U, Merenda, R, Donato, M, Rossi, G, Salizzoni, M, Franchello, A, Rizzetto, M, Pinzello, G, De Carlis, L, Toniutto, P, Andorno, E, Blasone L, Fagiuoli S, Colledan M, Strazzabosco M, Lenzi M, Floreani A, Burra P, Cillo U, Merenda R, Donato MF, Rossi G, Salizzoni M, Franchello A, Rizzetto M, Pinzello G, De Carlis L, Toniutto P, and Andorno E

Published
2007

3. Long term follow-up of liver transplantation (OLT) for cholestatic and autoimmune end stage liver diseases

Author

Blasone L, Fagiuoli S, Colledan M, Strazzabosco M, Lenzi M, Floreani A, Burra P, Cillo U, Merenda R, Donato MF, Rossi G, Salizzoni M, Franchello A, Rizzetto M, Pinzello G, De Carlis L, Toniutto P, Andorno E, Blasone, L, Fagiuoli, S, Colledan, M, Strazzabosco, M, Lenzi, M, Floreani, A, Burra, P, Cillo, U, Merenda, R, Donato, M, Rossi, G, Salizzoni, M, Franchello, A, Rizzetto, M, Pinzello, G, De Carlis, L, Toniutto, P, and Andorno, E

Subjects
Hepatology, Gastroenterology
Published
2007

5. [141] LONG TERM FOLLOW-UP OF LIVER TRANSPLANTATION (OLT) FOR CHOLESTATIC AND AUTOIMMUNE END STAGE LIVER DISEASES

Author

Blasone, L., primary, Fagiuoli, S., additional, Colledan, M., additional, Strazzabosco, M., additional, Lenzi, M., additional, Floreani, A., additional, Burra, P., additional, Cillo, U., additional, Merenda, R., additional, Donato, M.F., additional, Rossi, G., additional, Salizzoni, M., additional, Franchello, A., additional, Rizzetto, M., additional, Pinzello, G., additional, De Carlis, L., additional, Toniutto, P., additional, and Andorno, E., additional

Published
2007
Full Text
View/download PDF

7. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.

Author

Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, and Baldo V

Subjects
Adolescent, Adult, Cholagogues and Choleretics therapeutic use, Cholangitis, Sclerosing therapy, Female, Follow-Up Studies, Hepatitis, Autoimmune therapy, Humans, Immunosuppression Therapy, Male, Prospective Studies, Survival Analysis, Syndrome, Treatment Outcome, Ursodeoxycholic Acid therapeutic use, Cholangitis, Sclerosing physiopathology, Hepatitis, Autoimmune physiopathology
Abstract

Unlabelled: Autoimmune hepatitis/primary sclerosing cholangitis (AIH/PSC) overlap syndrome is a relatively uncommon variant of PSC., Aim: To evaluate the natural history of AIH/PSC overlap syndrome compared to a group of "classical" PSC., Methods: Forty-one consecutive PSC patients, with a regular follow-up of at least 2 years, were prospectively included in the study. Among these, 7 fulfilled the criteria for AIH/PSC overlap syndrome., Results: The AIH/PSC overlap group significantly differed from the "classical" PSC group in the following parameters: mean age at presentation (21.4 +/- 5.0 vs 32.3 +/- 10 years, p < 0.01), AST 191.0 +/- 14.8 vs 48.9 +/- 34.5 U/L, p < 0.005), ALT (357.0 +/- 26.5 vs 83.7 +/- 60.7 U/L, p < 0.005) and serum IgG (25.6 +/- 4.7 vs 12.9 +/- 6.0 mg/dl, p < 0.0001). The mean follow-up was similar in the 2 groups (93.3 +/- 65.9 vs 98.1 +/- 65.9 months respectively). Treatment included immunosuppression + ursodeoxycholic acid (UDCA) in the AIH/PSC overlap patients, and UDCA in the "classical" PSC group. Deaths were recorded only in the classical PSC group. The median survival in the latter group was 207 months (95% C.I. 87.6-326.4). The major events during the follow-up included: OLTx (1/7 vs 6/34), and neoplasms (only in the group of "classical" PSC). The new Mayo score prognostic index only increased significantly during follow-up in the "classical" PSC group (r2 0.8117, p < 0.01), Conclusion: Patients with AIH/PSC overlap syndrome seem to benefit from immunosuppression + UDCA therapy, survival is apparently better than in "classical" PSC condition.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results